CX003 / Checkmate Therapeutics - LARVOL DELTA

CX003, a first-in-class WNK3 inhibitor, enhances antitumor T cell immunity and synergizes with immune checkpoint blockade (ESMO-IO 2025) - "These dual mechanisms converged to amplify TCR signaling and improve tumor killing in Hepa1-6 OVA co-culture and in xenografts. It achieved a TGI 46% as monotherapy and 93% in combination with anti-PD-L1/anti-VEGFA therapy.Conclusions CX003 is an orally bioavailable, first-in-class WNK3 inhibitor that enhances T cell activity and reduces tumor PD-L1, supporting synergy with immune checkpoint blockade in HCC.Legal entity responsible for the study The author."

Checkpoint block • Checkpoint inhibition • IO biomarker • Hepatocellular Cancer • Oncology • Solid Tumor • CD4 • CD8 • GZMB • IFNG • IL2 • TNFA • WNK1